{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-100668","form_type":"8-K","ticker":"GPCR","cik":"0001888886","company_name":"Structure Therapeutics Inc.","filed_at":"2024-09-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.112104+00:00","generated_at":"2026-05-31T04:22:31.714536+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Structure Therapeutics appoints Blai Coll as CMO, Ashley Hall as CDO; Mark Bach departs in planned succession","bullets":["Mark Bach to depart as CMO effective Sept 18; will serve as advisor through Dec 31.","Blai Coll, previously VP of Clinical Development, promoted to CMO effective Sept 18.","Ashley Hall appointed as newly created Chief Development Officer role.","GSBR-1290 Phase 2b for obesity planned for Q4 2024.","Dr. Coll led GSBR-1290 program; Ms. Hall brings regulatory experience from Repatha."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-100668","json":"https://secwatch.observer/filing/0001104659-24-100668.json","markdown":"https://secwatch.observer/filing/0001104659-24-100668.md","text":"https://secwatch.observer/filing/0001104659-24-100668.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888886/000110465924100668/0001104659-24-100668-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888886/000110465924100668/tm2424160d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:22:31.714536+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"232a6b30db","claim":"Mark Bach departed as Chief Medical Officer at Structure Therapeutics Inc..","evidence_excerpt":"On September 12, 2024, Mark Bach, M.D., Ph.D. entered into a separation and consulting agreement (the “Bach Separation and Consulting Agreement”) with Structure Therapeutics Inc. (the “Company”) in connection with his departure as Chief Medical Officer (“CMO”) as part of a planned succession, effective as of September 18, 2024 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1888886/000110465924100668/0001104659-24-100668-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}